Biological studies of acute leukaemias are hampered by the technical difficulties involved in maintaining the viability and proliferation of patient-derived blasts in vitro. This is particularly true for studies trying to elucidate the nature and biology of leukaemia-propagating cells, the definition of which relies on functional assays of self-renewal/clonal expansion. Furthermore, the lack of critical niche interactions raises concerns over the validity of biological data generated purely in an in vitro setting, for example, when using derived cell line approaches 1 or patientderived cells with compromised viability. Developments in immunocompromised mouse models, notably NOD/scid and more recently the NOD/LtSz-scid IL-2 R g null (NSG) 2 and similar mice, have provided an opportunity to study leukaemia-
propagating cells in a bone marrow, albeit xenogeneic, microenvironment. [3] [4] [5] [6] Alongside this, there is a need to develop techniques to allow the labelling and tracking of leukaemic blasts in such xenotransplantation assays.
We have developed a protocol for the transduction of patientderived lymphoblastic leukaemic blasts using a lentiviral vector encoding both enhanced green fluorescent protein (EGFP), allowing in vitro analysis and cell sorting, and firefly Luciferase (fLuc), for in vivo bioluminescent imaging-pSLIEW (Supplementary Figure S1) . SLIEW virus was produced by transfection of HEK293T cells by calcium phosphate co-precipitation of equimolar amounts of the packaging vector pCMVD8.91, the envelope vector pMD2.G and the pSLIEW transfer vector. Patient-derived material was collected as part of initial diagnostic investigation with written informed consent in accordance with local review board approval (see Supplementary Methods). In the Lymphoid cells have been gated using forward and sideward scatter. The quadrant Q2 is determined by an untransduced sample to include p1% EGFP þ /CD19 þ cells. Population Q2 is then projected onto the central and right plots as green events, demonstrating unbiased transduction of all populations present. In this example, the majority of CD19 þ blasts are CD20 À /low. (c) Bioluminescent imaging of serially transplanted L4951 blasts. Primary recipient M6 (left-hand panels) was harvested at week 20 and bone marrow transplanted into secondary recipient M14 (right-hand panels), demonstrating bilateral femoral engraftment initially, followed by dissemination to spleen, liver and vertebrae. final protocol (used for transductions 9 and 10, see Supplementary  Table S1 ), blasts were resuspended at 1 Â 10 6 cells/ml in SFEM medium (Stem Cell Technologies, Grenoble, France) supplemented with 10% v/v fetal calf serum, 20 ng/ml recombinant IL-3, 10 ng/ml recombinant human IL-7 and 4 mg/ml polybrene. Cells were seeded into a 48-well plate at 5 Â 10 5 cells/well. Viral transduction was performed by spinfection at 900 g for 50 min at 34 1C (Figure 1a) . Following incubation overnight (37 1C, 5% CO 2 ), 350 ml of medium were removed and replaced with 850 ml fresh medium, supplemented as above. Transduction efficiency was assessed on day 3 or 4 post transduction by multicolour flow cytometry including CD19 PE, CD34 APC and CD20 PerCP Cy5.5, using a FACS Canto II (Becton Dickinson, Oxford, UK).
Multicolour flow cytometry demonstrated the unbiased transduction of all identified populations defined by the precursor B-cell surface markers CD19, CD20 and CD34 (Figure 1b) . During the development of the protocol, a total of 10 transductions (7 primary samples, 3 'primografted' samples, which had been passaged through mice) were performed on five different patientderived specimens with a mean transduction efficiency of 21% (range 2-42%) (Supplementary Table S1 ). The two final transductions were performed using viral stocks, which had previously been titrated using the B-lymphoblastic leukaemia cell line SEM 7 and shown in that system to have 5.6 Â 10 7 -1.2 Â 10 8 transducing units/ml. These experiments showed the relative transduction efficiency in L826 to be 0.5-3.4% and L839 to be 1.6-11%, compared with that in SEM.
To define a safe time point for transplantation, we analysed the persistence of infectious lentiviral particles in harvested supernatant. Surprisingly, substantial transduction of 293T cells was achieved with supernatant harvested at up to 4 days following spinfection (Supplementary Figure S2) , presumably resulting from the high viral titres required. We therefore introduced a stringent washing procedure to remove infectious particles following transduction (see Supplementary Methods).
To assess the engraftment potential of transduced cells, as well as the maintenance of transcription from the SFFV promoter, unsorted transduced cells were intrafemorally transplanted into NSG mice in two separate experiments. Engraftment was seen in 3/3 mice transplanted with 4.0 Â 10 4 transduced primografted blasts from a Philadelphia chromosome-positive sample L4951 (total cell dose 1 Â 10 5 cells per mouse) and 1/1 mice transplanted with 2 Â 10 4 transduced cells from the standard risk sample L578 (total cell dose 1 Â 10 6 cells). Bioluminescent imaging using the IVIS Spectrum (Caliper Life Sciences, Hopkington, MA, USA) demonstrated development of localised femoral engraftment, followed by dissemination of fLuc þ cells to alternative sites of haematopoiesis, including the contralateral femur, vertebrae and cranium as well as the spleen and liver (Figure 1c) . For sample L4951, bone marrow aspirates also showed engraftment of human CD19 þ cells with expression of EGFP (Figure 2a ). Furthermore, it was possible to quantify engraftment kinetics by analysis of bioluminescent images (Figure 2b ). Heavily engrafted mice were killed and found to have infiltrated bone marrow and grossly enlarged spleens (mean 0.6 g, range 0.41-0.8 g; normal spleen weight approximately 0.02-0.05 g) (Figure 2a) . Despite the low level of transduction of L578, threedimensional reconstructions were capable of localising fLuc þ blasts to the spleen, femurs and brain/meninges (Supplementary Figure S3) .
To further confirm the validity of the xenotransplantation model, the liver, spleen, kidneys and brain from the firstgeneration recipient of L578 were analysed histopathologically. This analysis showed widespread infiltration with leukaemic lymphoblasts expressing CD19, CD10, CD79a and TdT, characteristic of B-lymphoblastic leukaemia, as well as EGFP (Supplementary Figure S4) . Finally, flow cytometric analysis of individual tissues from three secondary mice engrafted with L578 demonstrated no organ-specific differential engraftment of transduced blasts (Supplementary Figure S5) .
Flow cytometric analysis of the primary transplant of Philadelphia chromosome-positive patient L4951, harvested from mice M4-M6 at week 20, showed that expression of EGFP in both bone marrow and spleen had decreased from 40% at initial transplantation to 5.3-10%. Harvested bone marrow and spleen from M4 and M6 was retransplanted fresh into a second generation of NSG mice. A total of 10 5 cells, corresponding to 5.4-10 Â 10 4 EGFP þ cells, were transplanted into each of 12 recipient mice. In contrast, EGFP expression following the primary engraftment of transduced blasts from the standard risk patient L578 was relatively stable (2% EGFP expression at transplantation) with harvested bone marrow and spleen demonstrating 1.6% and 1.9% EGFP expression, respectively. In this instance, 10 5 total bone marrow cells were retransplanted into each of three recipient mice, corresponding to 1.6 Â 10 3 EGFP þ cells. Secondary recipients of blasts harvested from primary recipients (M4 and M6) of sample L4951 demonstrated good engraftment with 11 of 12 mice (92%) of mice engrafting. Leukaemic cells from mice transplanted with material from M4 showed a further decrease in EGFP expression to between 0.2 and 1.8%. Somewhat to our surprise, however, cells from M6, which had been transplanted with 7.3% (bone marrow) or 8.0% (spleen) cells expressing EGFP, showed an expansion so that across all recipients, between 17 and 42% of cells were now EGFP þ . Again, EGFP expression was seen in all immunophenotypic populations (Figure 2a ). For the standard risk sample L578, all three secondary recipients of bone marrow harvested from the primary recipient showed good engraftment. At harvest, week 17, bone marrow expression of EGFP, which had been 1.6% at secondary transplant, varied between 0.3 and 2.9%.
In one final transplantation experiment, cells recovered from the second generation of mice transplanted with L4951 were sorted for CD19 þ EGFP þ (FACS Aria II, Becton Dickinson) and transplanted into 13 mice at a total cell dose of 1.5 Â 10 4 cells/ mouse. Three mice died before engraftment. Engraftment was seen in all 10 (100%) of the remaining mice.
Serial three-dimensional reconstructions of M35, a secondary recipient of L578, suggested an intriguing pattern of clonal seeding of secondary sites of engraftment, identified only in this specimen with a low level of transduction of 2% (Figure 2c ). Furthermore, we had observed a substantial increase in the proportion of EGFP þ blasts from L4951 between secondary transplant and harvest. To assess whether these findings represented a pattern of mono-/oligoclonal engraftment, we analysed the integration sites of the provirus using ligationmediated PCR directed at the 3 0 long terminal repeat. 8, 9 The substantial number of bands produced demonstrated diverse SLIEW integration sites, confirming the propagation of a polyclonal disease (Figure 2d) .
We have developed a protocol for the lentiviral transduction of patient-derived leukaemic blasts. The unbiased transduction of different leukaemic populations, combined with the serial engraftment of EGFP þ blasts confirms the transduction of the leukaemia-propagating cell compartment, even in one specimen with a low level of initial transduction. This is not unexpected as, unlike the stem cell hierarchy, which is found in acute myeloid leukaemia (AML), [10] [11] [12] leukaemia-propagating potential is present across blast populations defined by immunophenotypic markers of precursor B-cells 4, 5, 13 and is more common than in AML. 14 The lentiviral/xenotransplantation assay described makes possible the in vivo monitoring of leukaemia-propagating cells. Not only will this assay contribute to our understanding of the biology of these cells but also it has the potential to be adapted for a number of different purposes, including the monitoring of novel drug therapies, competitive transplantation of sorted populations and potentially the in vivo assessment of Letters to the Editor candidate stemness genes using either inhibitor or RNAi-based approaches. 
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